These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32378586)

  • 21. ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
    Valletta S; Dolatshad H; Bartenstein M; Yip BH; Bello E; Gordon S; Yu Y; Shaw J; Roy S; Scifo L; Schuh A; Pellagatti A; Fulga TA; Verma A; Boultwood J
    Oncotarget; 2015 Dec; 6(42):44061-71. PubMed ID: 26623729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.
    De I; Chittock EC; Grötsch H; Miller TCR; McCarthy AA; Müller CW
    Structure; 2019 Mar; 27(3):528-536.e4. PubMed ID: 30639226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
    Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
    J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase.
    Peng H; Cassel J; McCracken DS; Prokop JW; Sementino E; Cheung M; Collop PR; Polo A; Joshi S; Mandell JP; Ayyanathan K; Hinds D; Malkowicz SB; Harbour JW; Bowcock AM; Salvino J; Kennedy EJ; Testa JR; Rauscher FJ
    Mol Cancer Res; 2021 Jul; 19(7):1099-1112. PubMed ID: 33731362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PR-DUB maintains the expression of critical genes through FOXK1/2- and ASXL1/2/3-dependent recruitment to chromatin and H2AK119ub1 deubiquitination.
    Kolovos P; Nishimura K; Sankar A; Sidoli S; Cloos PA; Helin K; Christensen J
    Genome Res; 2020 Aug; 30(8):1119-1130. PubMed ID: 32747411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation.
    Campagne A; Lee MK; Zielinski D; Michaud A; Le Corre S; Dingli F; Chen H; Shahidian LZ; Vassilev I; Servant N; Loew D; Pasmant E; Postel-Vinay S; Wassef M; Margueron R
    Nat Commun; 2019 Jan; 10(1):348. PubMed ID: 30664650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.
    Köhnke T; Nuno KA; Alder CC; Gars EJ; Phan P; Fan AC; Majeti R
    Blood Cancer Discov; 2024 May; 5(3):202-223. PubMed ID: 38359087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
    Perez-Garcia V; Lea G; Lopez-Jimenez P; Okkenhaug H; Burton GJ; Moffett A; Turco MY; Hemberger M
    Elife; 2021 Jun; 10():. PubMed ID: 34170818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
    Wu X; Bekker-Jensen IH; Christensen J; Rasmussen KD; Sidoli S; Qi Y; Kong Y; Wang X; Cui Y; Xiao Z; Xu G; Williams K; Rappsilber J; Sønderby CK; Winther O; Jensen ON; Helin K
    Cell Res; 2015 Nov; 25(11):1205-18. PubMed ID: 26470845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
    Guo Y; Yang H; Chen S; Zhang P; Li R; Nimer SD; Harbour JW; Xu M; Yang FC
    Leukemia; 2018 Aug; 32(8):1834-1837. PubMed ID: 29743720
    [No Abstract]   [Full Text] [Related]  

  • 33. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
    Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG
    Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of ASXL1 in hematopoiesis and myeloid diseases.
    Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
    Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASXL1 mutation in clonal hematopoiesis.
    Fujino T; Kitamura T
    Exp Hematol; 2020 Mar; 83():74-84. PubMed ID: 31945396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
    Kolluri KK; Alifrangis C; Kumar N; Ishii Y; Price S; Michaut M; Williams S; Barthorpe S; Lightfoot H; Busacca S; Sharkey A; Yuan Z; Sage EK; Vallath S; Le Quesne J; Tice DA; Alrifai D; von Karstedt S; Montinaro A; Guppy N; Waller DA; Nakas A; Good R; Holmes A; Walczak H; Fennell DA; Garnett M; Iorio F; Wessels L; McDermott U; Janes SM
    Elife; 2018 Jan; 7():. PubMed ID: 29345617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
    Sahtoe DD; van Dijk WJ; Ekkebus R; Ovaa H; Sixma TK
    Nat Commun; 2016 Jan; 7():10292. PubMed ID: 26739236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1-associated protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes.
    Okino Y; Machida Y; Frankland-Searby S; Machida YJ
    J Biol Chem; 2015 Jan; 290(3):1580-91. PubMed ID: 25451922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
    Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
    J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
    J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.